oregovomab

Phase 2Monoclonal antibody

UUnither Pharmaceuticals

oregovomab is one of 139 small molecule programs targeting Ovarian Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

138

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian CarcinomaActive, not recruiting

Fallopian Tube CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Ovarian CarcinomaPhase 2

Active, not recruiting

Fallopian Tube CancerPreclinical

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Preclinical

108 2

oregovomab

UUnither Pharmaceuticals

Phase 2

1 3

Byetta

AstraZeneca

Preclinical

1 4

Medrol

Pfizer

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

ABI-007

Bristol-Myers Squibb

Preclinical

2 7

LDE225

Novartis

Preclinical

1 8

Thiazolidinediones

Sanofi

Preclinical

1 9

Meglitinides

Sanofi

Preclinical

1 10

Chemotherapy Agents

Takeda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Ovarian Cancer

NCT05605535

Q3 2028

Phase 3Active, not recruiting

Ovarian Cancer

NCT04498117

Clinical

Trials by Indication[1]

Ovarian Cancer8 trials

Clinical Trial for Ovarian Cancer (OvaRex®)

Terminated·UUnither Pharmaceuticals·Phase 3·NCT00050375·354 enrolled

The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer

Terminated·CCanariaBio Inc.·Phase 1·NCT03162562·10 enrolled

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

Active, not recruiting·CCanariaBio Inc.·Phase 2·NCT05605535·88 enrolled

Show 5 more trials

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Unknown status·CCanariaBio Inc.·Phase 1/2·NCT04938583·54 enrolled

A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer

Completed·QQuest PharmaTech Inc.·Phase 2·NCT01616303·97 enrolled

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting·CCanariaBio Inc.·Phase 3·NCT04498117·615 enrolled

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Active, not recruiting·CCanariaBio Inc.·Phase 2·NCT05335993·10 enrolled

Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment

Terminated·UUnither Pharmaceuticals·Phase 2·NCT00086632·40 enrolled

Peritoneal Cancer2 trials

Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy

Unknown status·AAltaRex·Phase 2·NCT00003634·400 enrolled

Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Unknown status·AAltaRex·Phase 2·NCT00004064·102 enrolled

Ovarian Carcinoma1 trial

Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma

Terminated·UUnither Pharmaceuticals·Phase 2·NCT00034372·102 enrolled

Carcinoma1 trial

A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma

Terminated·UUnither Pharmaceuticals·Phase 1/2·NCT00034138·24 enrolled

Fallopian Tube Cancer1 trial

Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy

Withdrawn·GGynecologic Oncology Group·N/A·NCT00551265

3 more indications

Pancreatic Cancer1 trial

Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer

Completed·UUniversity of Nebraska·Phase 2·NCT01959672·11 enrolled

Nivolumab1 trial

Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

Terminated·NNational Cancer Centre, Singapore·Phase 1/2·NCT03100006·13 enrolled

Clinical Trial1 trial

Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

Unknown status·NNational Cancer Centre, Singapore·Phase 1/2·NCT04620954·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for oregovomab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — oregovomab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for oregovomab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Unither Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: UUnither Pharmaceuticals

oregovomab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2028

Trials by Indication[1]

Ovarian Cancer8 trials

Peritoneal Cancer2 trials

Ovarian Carcinoma1 trial

Carcinoma1 trial

Fallopian Tube Cancer1 trial

Pancreatic Cancer1 trial

Nivolumab1 trial

Clinical Trial1 trial

References

Drug Info

Quick Facts

Related News